ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 262 filers reported holding ACADIA PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 1.06 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,939,136 | -27.1% | 332,972 | -16.2% | 0.00% | 0.0% |
| Q2 2023 | $9,520,604 | +6.7% | 397,520 | -16.1% | 0.00% | 0.0% |
| Q1 2023 | $8,920,115 | +4.6% | 473,970 | -11.5% | 0.00% | 0.0% |
| Q4 2022 | $8,529,045 | +8.4% | 535,744 | +11.4% | 0.00% | -33.3% |
| Q3 2022 | $7,868,000 | +24.2% | 480,920 | +6.9% | 0.00% | +50.0% |
| Q2 2022 | $6,336,000 | -45.0% | 449,694 | -5.5% | 0.00% | -33.3% |
| Q1 2022 | $11,525,000 | +639.7% | 475,866 | +613.0% | 0.00% | – |
| Q4 2021 | $1,558,000 | +31.1% | 66,746 | -6.7% | 0.00% | – |
| Q3 2021 | $1,188,000 | -22.6% | 71,542 | +13.7% | 0.00% | – |
| Q2 2021 | $1,535,000 | -11.7% | 62,916 | -6.7% | 0.00% | – |
| Q1 2021 | $1,739,000 | -97.3% | 67,441 | -94.3% | 0.00% | -100.0% |
| Q4 2020 | $63,757,000 | +413.1% | 1,192,615 | +295.9% | 0.02% | +375.0% |
| Q3 2020 | $12,425,000 | -16.0% | 301,223 | -1.3% | 0.00% | -20.0% |
| Q2 2020 | $14,788,000 | -39.0% | 305,094 | -46.8% | 0.01% | -50.0% |
| Q1 2020 | $24,235,000 | -62.8% | 573,626 | -62.4% | 0.01% | -50.0% |
| Q4 2019 | $65,208,000 | -55.9% | 1,524,260 | -62.9% | 0.02% | -48.7% |
| Q3 2019 | $147,973,000 | +37.9% | 4,111,525 | +2.4% | 0.04% | +39.3% |
| Q2 2019 | $107,334,000 | +945.6% | 4,015,482 | +950.3% | 0.03% | +833.3% |
| Q1 2019 | $10,265,000 | +24.0% | 382,311 | -25.3% | 0.00% | 0.0% |
| Q4 2018 | $8,276,000 | -22.6% | 511,787 | -0.7% | 0.00% | 0.0% |
| Q3 2018 | $10,695,000 | +136.7% | 515,164 | +74.1% | 0.00% | +200.0% |
| Q2 2018 | $4,519,000 | -33.5% | 295,903 | -2.1% | 0.00% | -66.7% |
| Q1 2018 | $6,791,000 | -87.3% | 302,238 | -82.9% | 0.00% | -84.2% |
| Q4 2017 | $53,277,000 | -29.1% | 1,769,414 | -11.3% | 0.02% | -32.1% |
| Q3 2017 | $75,125,000 | +35.1% | 1,994,267 | +0.0% | 0.03% | +64.7% |
| Q2 2017 | $55,603,000 | -1.8% | 1,993,659 | +21.1% | 0.02% | -10.5% |
| Q1 2017 | $56,623,000 | +68.1% | 1,646,953 | +41.0% | 0.02% | +72.7% |
| Q4 2016 | $33,683,000 | -9.0% | 1,167,950 | +0.4% | 0.01% | -15.4% |
| Q3 2016 | $37,023,000 | -1.1% | 1,163,870 | +0.9% | 0.01% | -7.1% |
| Q2 2016 | $37,436,000 | +16.4% | 1,153,267 | +0.2% | 0.01% | +7.7% |
| Q1 2016 | $32,166,000 | -28.8% | 1,150,443 | -9.2% | 0.01% | -27.8% |
| Q4 2015 | $45,154,000 | +9.7% | 1,266,595 | +1.8% | 0.02% | +5.9% |
| Q3 2015 | $41,157,000 | -26.3% | 1,244,525 | -6.6% | 0.02% | -22.7% |
| Q2 2015 | $55,823,000 | +263.4% | 1,332,936 | +182.8% | 0.02% | +266.7% |
| Q1 2015 | $15,363,000 | +5.8% | 471,381 | +3.0% | 0.01% | 0.0% |
| Q4 2014 | $14,527,000 | +28.2% | 457,530 | 0.0% | 0.01% | +20.0% |
| Q3 2014 | $11,328,000 | +9.6% | 457,530 | 0.0% | 0.01% | +25.0% |
| Q2 2014 | $10,336,000 | -63.8% | 457,530 | -61.1% | 0.00% | -66.7% |
| Q1 2014 | $28,589,000 | +159.8% | 1,175,066 | +166.9% | 0.01% | +200.0% |
| Q4 2013 | $11,004,000 | -55.7% | 440,343 | -51.3% | 0.00% | -63.6% |
| Q3 2013 | $24,837,000 | +144.0% | 904,145 | +61.2% | 0.01% | +120.0% |
| Q2 2013 | $10,179,000 | – | 560,812 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |